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Abstract 
The serine/threonine phosphatase inhibitor, okadaic acid (OA), exerted several insulin-like effects in rat adipose cells 
and was, in part, synergistic with insulin. OA stimulated glucose transport activity, altered the electrophoretic mobility of 
IRS-1, increased the phosphorylation f the MAP-kinases ERK 1 and 2 on tyrosine sites, markedly increased MAP kinase 
activity and also acted synergistically with insulin in activating these enzymes. However, OA did not increase PI 3-kinase 
activity or the tyrosine phosphorylation f key upstream proteins in insulin's signaling cascade. Staurosporine virtually 
completely inhibited the insulin-stimulated glucose transport and MAP kinase activation in spite of a maintained high PI 
3-kinase activity. In contrast, the effects of OA alone or in the presence of insulin were less, or not at all, affected. These 
data suggest that OA exerts an insulin-like effect through a serine/threonine-related pathway which is distinct from, but 
converges with, that of insulin downstream PI 3-kinase and upon which stanrosporine exerts an inhibitory effect. 
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I. Introduction 
Abbreviations: OA, okadaic acid; PI 3-kinase, phosphatidyli- 
nositol 3-kinase; IRS, insulin receptor substrate; MAP-kinase, 
mitogen-activated protein kinase; GLUT, glucose transporter; 
MBP, myelin basic protein. 
* Corresponding author. Fax: +46 31 825330. 
1 Present address: Lundberg Laboratory for Diabetes Research, 
Department of Internal Medicine, Sahlgrenska University Hospi- 
tal, S-413 45 Gothenburg, Sweden. 
Okadaic acid (OA) is a cell permeable complex 
fatty acid polyketal which specifically inhibits the 
serine/threonine phosphatases 1 and 2 A [1,2] and 
promotes serine/threonine phosphorylation of sev- 
eral proteins in different cells [3]. 
OA has been shown to be a partial insulinomimetic 
agent and to enhance glucose transport activity and 
translocation of both GLUT 4 and IGF II receptors in 
isolated rat adipocytes [3-5]. However, OA also par- 
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tially inhibits the ability of insulin to stimulate these 
processes. Serine/threonine phosphorylation of the 
insulin receptor substrate 1 (IRS-1) by OA was re- 
cently shown to inhibit its subsequent tyrosine phos- 
phorylation by the insulin receptor tyrosine kinase 
and also to inhibit the binding of the p85 and p110 
subunits of phosphatidylinositol 3-kinase (PI3-kinase) 
to IRS-1 [6]. Binding and activation of PI 3-kinase 
seem to be essential for several effects of insulin 
including the increase in glucose transport and GLUT 
4 translocation [7,8]. 
The role of protein kinase C (PKC), a 
serine/threonine kinase, in insulin signaling and 
transduction is currently unclear. However, it has 
been reported that insulin activates PKC in rat 
adipocytes [9,10]. Further support for a potential role 
of PKC in insulin action was recently obtained by 
Nishimura nd Simpson [11]. These authors reported 
that staurosporine, a well recognized inhibitor of 
PKC, markedly reduced insulin-stimulated glucose 
transport as well as the translocation of GLUT 4 to 
the plasma membrane. 
In the current study, we utilized OA and stau- 
rosporine to explore the role of serine/threonine 
phosphorylation i  insulin action. We present evi- 
dence that staurosporine completely obliviates the 
stimulatory effect of insulin on glucose transport and 
that this effect is overcome by OA. The inhibitory 
effect of staurosporine on insulin action is exerted at 
a level downstream PI 3-kinase activation. Further- 
more, both OA and insulin activate the mitogen- 
activated protein kinases (MAP kinases) and, when 
combined, exert a synergistic effect. Thus, OA exerts 
several insulin-like ffects through a serine/threonine 
related pathway that is distinct from but, in part, 
synergistic with that of insulin and upon which stau- 
rosporine xerts an inhibitory effect. 
was from LC Laboratories (Woburn, MA). Antiphos- 
photyrosine monoclonal antibody (clone 4G10), anti- 
Rat MAP kinase R2 (erkl-ct) polyclonal antibodies 
and anti-IRS-1 polyclonal antibodies were purchased 
from Upstate Biotechnology (Lake Placid, NY). Pro- 
tein-A Sepharose was from Pharmacia (Piscataway, 
N J) and radiochemicals were from ICN (Costa Mesa, 
CA) or from Du Pont-New England Nuclear (Boston, 
MA). 
2.2. Animals and cell preparation 
Male rats (170-200 g; CD strain, Charles River 
Breeding Laboratories, Wilmington, MA) were used 
throughout. The rats were anesthetized with CO2/O 2 
(70%:30%) and killed by decapitation. Cells were 
isolated with collagenase (type 1, Worthington, Free- 
hold, NJ) as described previously [12]. 
2.3. Incubation of adipose cells and determination of 
glucose transport activity 
All incubations were carried out at 37°C in a 
Krebs-Ringer bicarbonate-Hepes buffer, pH 7,4, con- 
taining 10 mM NaHCO 3, 30 mM Hepes, 400 nM 
adenosine and 5% (w/v) bovine serum albumin 
(fraction V; Jutergen, Purchase, NY). Isolated 
adipocytes were distributed into plastic vials (0.8-1.2 
• 10  6 cells/ml) in a final incubation volume of 400 
Ixl. Cells were preincubated with the different reagents 
for 5 min, and the incubation was continued with or 
without the indicated concentrations of insulin. 10 
min after the addition of insulin, 400 ixl of cells were 
centrifuged through dinonylphthalate and resus- 
pended in lysis medium (see below). After 15 min 
glucose transport activity was determined in separate 
vials by the 3-O-methylglucose uptake technique as 
described elsewhere [ 11 ]. 
2. Experimental procedures 2.4. Immunoprecipitations 
2.1. Materials 
Sodium orthovanadate, staurosporine, wortmannin, 
phorbol 12-myristate 13-acetate (PMA) and myelin 
basic protein (MBP) from bovine brain were pur- 
chased from Sigma (St. Louis, MO); bovine insulin 
was from Gibco (Grand Island, NY) and okadaic acid 
Adipose cells that were centrifuged through di- 
nonylphthalate were lysed with 0.4 ml of a solution 
(Lysis Medium) containing 25 mM Tris-HCl, pH 7.4, 
0.5 mM EGTA, 25 mM NaC1, 1% NP-40, 1 mM 
sodium orthovanadate, 10 mM NaF, 0.2 mM leu- 
peptin, 1 mM benzamidine, and 0.1 mM 4-(2- 
Aminoethyl)benzene sulfonyl fluoride (Calbiochem, 
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La Jolla, Ca) (AEBSF) and rocked for 40 min at 4°C. 
Detergent insoluble material was sedimented by cen- 
trifugation at 12000 × g for 10 min at 4°C and the 
supernatants collected. Irnmunoprecipitations f tyro- 
sine phosphorylated proteins were performed using 
monoclonal antiphosphotyrosine a tibodies at a con- 
centration of 5 txg/ml for 2 h. Subsequently, the 
immune complexes were bound to protein A-Sep- 
harose CL4B (40 txl of hydrated beads/sample) by 
incubation for 1 h at 4°C. The immunoprecipitates 
were washed twice with phosphate-buffered saline 
containing 1% Nonidet p-40 and 200 txM vanadate, 
once with 0.5 M LiC1, 100 mM Tris-HCl(pH 7.4), 
200 IxM vanadate and twice with 10 mM Tris-HC1 
(pH 7.4), 100 mM NaC1, 1 mM EDTA and 200 IxM 
vanadate. 
2.5. Phosphatidylinositol 3-kinase activity 
PI 3-kinase assay was performed irectly on the 
immunoprecipitates as previously described [13]. Af- 
ter the washings described above, 6 txl of a mixture 
of phosphatidylinositol (10 p~g/sample) and phos- 
phatidylserine (2.5 ixg/sample) were added to the 
beads and the reaction was started by the addition of 
30 txl of a reaction mixture consisting of 40 mM 
Hepes pH 7.5, 20 mM MgC1 z and 50 IxM [~/-32p]ATP 
(0.2 mCi/ml). After 15 rain at 30°C the reaction was 
stopped by the addition of 40 Ixl HC1 (4 N) and 160 
txl CHC13/methanol (1:1). The organic phase was 
extracted and applied to a silica gel thin-layer chro- 
matography plate precoated with 1% potassium ox- 
alate (Analtech, Newark, DE). Thin-layer cromatog- 
raphy  p la tes  w ere  deve loped  in 
CHC13/CH 3OH/H 20 /NH 4OH (60:47:11.3:2), 
dried and visualized by autoradiography. The radioac- 
tivity was quantitated with a Phospholmager (Molec- 
ular Dynamics, Sunnyvale, CA). 
ing to the recomendations of the manufacturer and 
the proteins were detected by enhanced chemilumi- 
nescence using horseradish peroxidase-labeled sec- 
ond antibodies (Amersham, Buckinghamshire, UK), 
and the intensity of the bands were quantitated using 
a laser densitometer (Molecular Dynamics, Sunny- 
vale, CA) and expressed in arbitrary units. In some 
cases, the MAP kinases and IRS-1 were detected by 
using 0.2 ~xCi/ml 125I-labelled Protein A. 
2.7. Immunoprecipitation a d assay of MAP-kinase 
activity 
Adipose cell lysates were rocked for 40 min at 
4°C. Detergent-insoluble material was sedimented by 
centrifugation at 12000 × g for 10 min at 4°C and 
the supernatants were incubated overnight with 5 
txg/tube of affinity purified anti-rat MAP-kinase R2 
antibody. Subsequently, the incubation was continued 
for 1 h with 20 lxl of protein A-Sepharose CL4B 
beads. The beads were washed twice with Lysis 
Medium and resuspended in 0.3 ml of MAP-kinase 
assay medium containing 25 mM Tris-C1, pH 7.5, 0.5 
mM EGTA, 10 mM MgCI 2, 1 mM DTT and 0.1 
mg/ml  BSA. 
MAP kinase activity was assayed as described 
[14]. Briefly, 20 ixl aliquots of the resuspended im- 
munoprecitates were incubated for 10 min in assay 
medium supplemented with 2 txCi [~/-32p]ATP, 100 
txM ATP, 2 ng/ml  of the peptide inhibitor of 
cAMP-dependent protein kinase and 150 txg/ml 
MBP at 29°C in a total volume of 40 Ixl. The reaction 
was terminated by spotting an aliquot of the samples 
on phosphocellulose paper filters (Whatman P81, 
Clifton, NJ). After 5 washes in 1% (v/v) orthophos- 
phoric acid, incorporation of radiophosphate was de- 
termined by liquid scintillation counting. 
2.6. Immunoblotting 3. Results 
Whole cell lysates or immunoprecipitations were 
boiled in Laemmli buffer containing 55 mM dithio- 
threitol for 5 min. The samples were analyzed by 
SDS-polyacrylamide gel electrophoresis. Proteins 
were transferred from the gel to the nitrocellulose 
sheets and blocked in 5% milk. The blots were 
probed with the different primary antibodies accord- 
3.1. Glucose transport 
OA alone exerted a partial insulinomimetic effect 
but, when combined with insulin, reduced the effect 
of a maximal insulin concentration ~ 50% (Table 1). 
The effect of OA alone was partly inhibited by 
staurosporine while the small stimulatory effect of 
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Table 1 
Rates of glucose transport measured with 3-O-[14C]methylglu - 
COSC 
Additions Glucose transport 
(fmol/cell  per min) 
No additions 0.07 
+ OA 0.68 
+ OA + staurosporine 0.24 
+ Insulin 4.24 
+ Insulin + staurosporine 0.43 
+ Insulin + staurosporine + OA 2.25 
+ Insulin + OA 2.80 
Both OA and insulin alone altered the elec- 
trophoretic mobility of the p 42 MAP kinase (Fig. 
lb). This change was even more pronounced by the 
combination of these agents. Staurosporine again pre- 
vented the effect of insulin but not that of OA alone 
or in combination with insulin (Fig. lb). Correspond- 
ing data were seen with the p 44 MAP kinase (data 
not shown). The changes in mobility were paralleled 
by the degree of tyrosine phosphorylation (data not 
shown). 
Isolated rat adipocytes were preincubated for 5 min with the 
various agents hown (okadaic acid (OA) 1 ~M; staurosporine 6 
txM). Insulin (6.7 nM) was then added as shown for another 10 
min before 3-O-[~4C]methylglucose was added to measure the 
rate of glucose transport as previously described [9]. The results 
are the means of 2-3 experiments. 
PMA (1 txM) was completely prevented (data not 
shown). Furthermore, the stimulatory effect of insulin 
was virtually completely blocked by staurosporine 
(~ 90%) and staurosporine alone had no effect (data 
not shown) However, this marked inhibitory effect of 
staurosporine was prevented by the concomitant addi- 
tion of OA. Rate of glucose transport was then 
similar to that seen with the combination of insulin 
and OA (Table 1). 
3.2. MAP kinase activity and phosphorylation 
MAP kinase activity was markedly increased by 
OA alone and to a similar extent as with insulin (Fig. 
1 a). The combination of these two agents produced a
synergistic effect. Staurosporine again completely in- 
hibited the insulin-stimulated MAP kinase activity. 
However, the effect of OA alone was not inhibited by 
staurosporine and the MAP kinase activity seen with 
the combination of insulin and OA was again consis- 
tent with a restitution of the insulin-stimulated activ- 
ity, i.e., the combination produced a greater effect 
than either agent alone (Fig. la). 
To examine the potential role of PKC, the effect of 
PMA on MAP kinase activity was also measured. 
PMA enhanced MAP kinase activity to a lesser ex- 
tent than insulin alone. However, similar to insulin, 
the effect of PMA was completely antagonized by 
staurosporine (Fig. la). 
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Fig. 1. (a) Isolated rat adipocytes were preincubated for 5 min 
with okadaic acid (OA) or staurosporine (St) and then with or 
without insulin (INS) or phorbol ester (PMA 1 ixM) as indicated 
for 10 min. MAP kinase immunoprecipitates were assayed for 
MAP-kinase activity with the exogenous ubstrate MBP as de- 
scribed in the Section 2. Results are means _ S.E. of 2-3 experi- 
ments. (b) Mobility shift of p 42 and p 44 MAP kinases. 
Treatment of the cells was the same as in Fig. 1 and immunoblots 
of whole cell lysates with anti MAP-kinase polyclonal antibodies 
were performed as described in the Section 2. 
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Fig. 2. Effect of okadaic acid and/or insulin on tyrosine phos- 
phorylation of the insulin receptor, IRS-1, p 60 and p 120. 
Anti-phosphotyrosine immunoblots of whole cell lysates were 
performed as described in the Section 2. 
3.3. Tyrosine phosphorylation of the insulin receptor 
(IR), IRS-1, p 60 and p 120 
We examined the effects of OA and staurosporine 
on the phosphorylation :state of key proteins in the 
insulin signaling cascade, IR and IRS-1, as well as 
two other proteins, p 60 and p 120, that exhibited 
increased tyrosine phosphorylation (Fig. 2). OA alone 
did not increase the tyrosine phosphorylation of any 
of these proteins but, in contrast, reduced the 
insulin-stimulated phosphorylation of IRS-1 and p 
120, a protein that appeared to be constitutively 
phosphorylated since we saw no consistent effect of 
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Fig. 4. PI 3-kinase activity was measured in antiphosphotyrosine 
immunoprecipitates of cells incubated for 10 min with insulin 
(INS) in the presence or absence of okadaic acid (OA) and/or 
staurosporine (St). Autoradiogram (top panel) and quantification 
of the radioactivity with a PhosphoImager. The data presented are 
representative of at least hree different experiments with similar 
results. 
insulin-mediated increase in tyrosine phosphate con- 
tent of p 60 as well as p 120 but had no effect on the 
tyrosine phosphorylation of IR or IRS-1. 
3.4. Effect of staurosporine on IRS-1 phosphorylation 
anti-IRS 1 
I I I I I I I 
The electrophoretic mobility of IRS-1 was altered 
by insulin or OA alone and, in particular, by the 
combination of these agents (Fig. 3). The apparent 
hyperphosphorylation by insulin and OA led to a 
considerable broadening of the IRS-1 band. Stau- 
rosporine reduced the mobility shift of IRS-1 seen 
with insulin and OA alone and also reduced the effect 
of the combination of insulin and OA (Fig. 3). 
3.5. Effect of staurosporine and okadaic acid on 
insulin-stimulated PI 3-kinase activity 
Fig. 3. Mobility shift of IRS-I by okadaic acid (OA) and insulin 
(Ins) in the absence or presence of staurosporine (St). Treatment 
of the rat adipocytes was the same as in Fig. 1, and whole cell 
lysates were then immunoblotted with anti-IRS-1 C-terminal 
polyclonal antibody as described in the Section 2. 
PI 3-kinase activity was measured in antiphospho- 
tyrosine immunoprecipitates of proteins from cells 
treated with okadaic acid, staurosporine and/or  in- 
sulin. As shown in Fig. 4, okadaic acid or stau- 
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rosporine alone (data not shown) had no effect on PI 
3-kinase activity while insulin induced 15-20-fold 
increase in activity. Okadaic acid markedly reduced 
the stimulatory effect of insulin both in the presence 
and absence of staurosporine. However, staurosporine 
alone did not inhibit the insulin-stimulated PI 3-kinase 
activity but, in fact, further enhanced the activation 
(Fig. 4). 
4. Discussion 
The present study shows that OA exerts several 
insulinomimetic effects such as stimulating lucose 
transport and increasing MAP kinase activity. Fur- 
thermore, OA overcame the inhibitory effects of stau- 
rosporine and restored insulin action in cells exposed 
to the combination of these two agents. This was true 
for both glucose transport, MAP kinase phosphoryla- 
tion and activity. However, the insulinomimetic ef- 
fects of OA are not associated with an increased 
tyrosine phosphorylation of key proteins involved in 
insulin action such as IR, IRS-1, and p 60, which 
may represent shc [15,16]. In fact, OA, probably by 
enhancing serine/threonine phosphorylation, reduced 
the insulin-stimulated tyrosine phosphorylation of 
IRS-1. However, the MAP kinases ERK 1 and 2 were 
clearly phosphorylated on tyrosine sites by OA alone 
(data not shown). 
Taken together, these findings suggest that OA 
exerts its insulinomimetic effects through a putative 
serine/threonine-related pathway which reduces the 
upstream insulin-stimulated tyrosine phosphorylation 
but also seems to converge with that of insulin 
downstream PI 3-kinase since tyrosine phosphoryla- 
tion was enhanced and both agents synergistically 
increased the MAP kinase activity. Alternatively, both 
tyrosine- and serine/ threonine-related phosphatases 
are involved in the regulation of the phosphorylation 
and activity of the MAP kinases. This latter concept 
is supported by the finding of Anderson et al. [17] 
that the addition of either phosphatase 2 A, a 
phosphoserine/phosphothreonine-speci f ic  phos- 
phatase inhibited by OA, or a phosphotyrosine- 
specific phosphatase inhibited the activity of purified 
MAP kinase. OA has previously been shown to 
enhance MAP kinase activity [18] but the synergistic 
effect with insulin is a novel finding as well as the 
differential sensitivity of OA and insulin to stau- 
rosporine. 
The possibility that OA exerts its insulinomimetic 
effect through a serine/ threonine related pathway 
which is distinct from, but converges with, that of 
insulin is supported by the finding that staurosporine, 
a non-selective inhibitor of PKC, virtually completely 
inhibited the insulin-stimulated glucose transport, 
while the effect on OA alone was much less or not at 
all reduced. In addition, OA restored the insulin 
effects and overcame the inhibitory action of stau- 
rosporine. Importantly, staurosporine did not inhibit 
the insulin-stimulated-PI 3-kinase activity nor the 
association of the p85 subunit of PI 3-kinase with 
IRS-1 (data not shown), suggesting that its action, 
like that of OA, was exerted downstream of or was 
independent of PI 3-kinase. In agreement with this, 
we have evidence that the PI 3- kinase inhibitor, 
wortmannin, is not inhibitory to the insulinomimetic 
effect of OA on glucose transport activity while the 
effect of insulin is completely prevented (data not 
shown). However, it is interesting that increased glu- 
cose transport and GLUT4 translocation can also be 
elicited in skeletal muscle through both wortmannin- 
sensitive and -insensitive processes [19]. It seems that 
similar processes are also present in rat adipocytes. PI 
3-kinase is a lipid and serine/threonine kinase [20] 
which becomes activated by the binding of the p85 
regulatory subunit to IRS-1 [20]. However, 
serine/threonine phosphorylation of IRS-1 seems to 
impair the binding of p85 [6]. Thus, a differential 
effect of wortmannin on OA and insulin action is not 
unexpected. 
It is interesting to note that staurosporine virtually 
completely inhibited the stimulatory effect of insulin 
on glucose transport while the PI 3-kinase activity 
was unchanged or even further stimulated. Thus, a 
dissociation between insulin-stimulated PI 3-kinase 
activity and glucose transport was clearly evident. 
However, in agreement with previous studies [6] OA 
reduced the insulin-stimulated glucose transport and 
PI 3-kinase activity. 
The electrophoretic mobility of IRS-1 was altered 
in lysates from cells exposed to OA. This finding, 
combined with a reduced tyrosine phosphorylation, is 
consistent with an effect of OA to increase 
serine/threonine phosphorylation f IRS-1 [6]. Inter- 
estingly, staurosporine inhibited the mobility of IRS- 1 
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following both insulin and OA exposure. These find- 
ings are consistent with an inhibitory effect of stau- 
rosporine on serine/threonine phosphorylation of 
IRS- 1. 
The role of PKC for the effects of insulin and OA 
is unclear. Staurosporine is not a specific inhibitor of 
PKC and has been reported to reduce both cAMP-de- 
pendent protein kinase activity, p 60 V-src tyrosine 
kinase and a cytoplasmic tyrosine kinase activated by 
vanadate [21-23]. Thus, we can not exclude that the 
inhibitory effect of staurosporine on insulin action is 
mediated through the inhibition of other kinases than 
PKC. However, a role of PKC is supported by the 
ability of staurosporine atthe low concentration used 
(6 I~M) to inhibit botlh PMA-stimulated glucose 
transport and MAP kinase activity. Further support 
for the importance of PKC and/or other downstream 
serine/threonine kinases is the observation that stau- 
rosporine did not affect the insulin-stimulated tyro- 
sine phosphorylation f the insulin receptor or IRS-1 
or the activation of PI 3-kinase. 
The ability of OA to restore insulin action in the 
presence of staurosporine is not due to a restoration 
of tyrosine phosphorylation f key proteins in insulifis 
signalling cascade. Similarly, Shisheva nd Shechter 
[24] concluded that the interaction between these 
agents occurs at a level downstream the insulin recep- 
tor. Our results are consistent with an increased 
serine/threonine phosphorylation of IRS-1, as well 
as other proteins, leading to the insulin-mimetic ef- 
fects as well as the rest,oration of insulin action on 
glucose transport and MAP kinase activity in the 
presence of staurosporine. The detailed molecular 
mechanisms involved are currently unclear. 
In summary, the present data show that OA exerts 
its insulinomimetic effec~:s through a mechanism that 
is distinct from, but pan:ly converging with, that of 
insulin and which is independent of PI 3-kinase 
activation. A synergistic effect is seen at the level of 
MAP kinase activation and tyrosine phosphorylation. 
Staurosporine inhibited the stimulatory effect of in- 
sulin on both glucose transport and MAP kinase 
activity while this inhibition was overcome by the 
simultaneous addition of OA. We are currently ex- 
ploring the mechanisms whereby OA exerts its in- 
sulin-like effects and also whether other type 1 and 2 
A serine/threonine phosphatase inhibitors exert simi- 
lar effects. 
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